The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS

The long-awaited Risk Evaluation & Mitigation Strategy for Aranesp and Procrit is here. For the oncology indication, it requires provider training program enrollment. It may not seem like the best outcome for Amgen and J&J, but there are some upsides.

Neither Amgen nor Johnson & Johnson could possibly have imagined three years ago that they would be registering oncologists in a program intended to curtail use of two blockbuster products, the erythropoiesis stimulating agents Aranesp (darbepoetin) and Procrit (epoetin).

But, after a long and difficult period of safety scrutiny, that is exactly what the companies are doing, thanks to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

PS-AgencyLeadership (Premium-1): Study Reveals How Immune System of Astronauts Breaks Down

Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.

Nancy Test Circulable Section Geography

 

This is a short description

test-sabbah

 
• By 

Test -Sabbah

Akash test for clone

 
• By 

Test article to check the clone issue

More from Pink Sheet

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers

 
• By 

It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.